Literature DB >> 8883235

Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.

S Mercadante, G Avola, S Maddaloni, G Salamone, F Aragona, V Rodolico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8883235     DOI： 10.1007/bf01788848

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  4 in total

1.  Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients.

Authors:  S Mercadante; S Maddaloni
Journal:  J Pain Symptom Manage       Date:  1992-11       Impact factor: 3.612

2.  Control of emesis in bowel obstruction in terminally ill patients.

Authors:  D Khoo; J Riley; J Waxman
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

3.  Does vasoactive intestinal polypeptide mediate the pathophysiology of bowel obstruction?

Authors:  M D Basson; L P Fielding; A J Bilchik; K A Zucker; G H Ballantyne; J Sussman; T E Adrian; I M Modlin
Journal:  Am J Surg       Date:  1989-01       Impact factor: 2.565

4.  Critical operative management of small bowel obstruction.

Authors:  R H Stewardson; C T Bombeck; L M Nyhus
Journal:  Ann Surg       Date:  1978-02       Impact factor: 12.969
  4 in total
  1 in total

1.  Palliative management of malignant bowel obstruction in terminally ill patient.

Authors:  Darshit A Thaker; Bruce C Stafford; Luke S Gaffney
Journal:  Indian J Palliat Care       Date:  2010-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.